FDA staff cite concerns over Amgen's cancer vaccine data
April 27, 2015 at 08:38 AM EDT
April 27 (Reuters) - The U.S. Food and Drug Administration should not consider an accelerated review for drugmaker Amgen Inc's marketing application for its skin cancer vaccine, FDA staff reviewers concluded in documents released on Monday.